Medicine and Dentistry
Thrombotic Thrombocytopenic Purpura
100%
Disease
47%
Antiphospholipid Syndrome
40%
Sickle-Cell Disease
32%
Thrombosis
32%
Bleeding
29%
Atypical Hemolytic Uremic Syndrome
25%
Platelet
23%
Thrombocytopenia
23%
Antiphospholipid Antibody
21%
Cardiovascular Disease
18%
Complement Activation
18%
Microangiopathy
18%
Eculizumab
17%
Bloodless Surgery
17%
Apoplexy
16%
Anticoagulation
16%
Von Willebrand Factor Cleaving Proteinase
15%
Infarction
13%
Quality of Life
12%
Venous Thromboembolism
12%
Survivorship in Cancer Care
12%
Myeloproliferative Neoplasm
11%
Heparin-Induced Thrombocytopenia
11%
Complement Component C5b
10%
Targeted Therapy
10%
Hazard Ratio
9%
Pathophysiology
9%
Complement Inhibition
9%
Prostate Cancer
9%
Heparin
8%
Health Care Cost
8%
Catastrophic Antiphospholipid Syndrome
8%
Coagulopathy
8%
Pediatrics
8%
Elevated Transaminases
8%
Pediatrics Patient
7%
Von Willebrand Factor
7%
Clinician
7%
Biological Marker
7%
Systemic Lupus Erythematosus
7%
Odds Ratio
7%
Gene Mutation
7%
Ex Vivo
7%
Liver Graft
7%
Idiopathic Thrombocytopenic Purpura
6%
COVID-19
6%
Pre-Eclampsia
6%
Liver Cirrhosis
6%
Hydroxyurea
6%
Keyphrases
Immune Thrombocytopenic Purpura
45%
Antiphospholipid Syndrome
40%
Thrombotic Thrombocytopenic Purpura
38%
Survivors
27%
Thrombosis
26%
Thrombocytopenia
25%
Atypical Hemolytic Uremic Syndrome (aHUS)
21%
Sickle Cell Disease
21%
Thrombotic Microangiopathy
19%
Antiphospholipid Antibodies
17%
Clinical Outcomes
16%
Eculizumab
16%
Remission
15%
Alternative Complement Pathway
14%
Confidence Interval
14%
Bleeding
13%
Odds Ratio
13%
Cardiovascular Disease
12%
ADAMTS13
12%
Bloodless Surgery
11%
Myeloproliferative Neoplasms
11%
Survivorship
11%
Hereditary Hemorrhagic Telangiectasia
11%
Posttraumatic Stress Disorder
11%
Thrombocytopenia in Pregnancy
11%
Sickle Cell Anemia
11%
Older Adults
11%
Clinical Remission
10%
Anticoagulation
10%
Low Platelet Count
9%
Stent Thrombosis
9%
Pregnancy Outcome
9%
Aspirin
9%
Preeclampsia
9%
Rituximab
8%
Elevated Liver Enzymes
8%
Incidental
8%
Single Institution
8%
Hazard Ratio
8%
Early Mortality
8%
Risk Factors
8%
Germ Cells
8%
Complement Inhibition
7%
United States
7%
Pediatric
7%
Length of Stay
7%
Systemic Lupus Erythematosus
7%
Transfusion
7%
Catastrophic Antiphospholipid Syndrome
7%
Immune Thrombocytopenia
7%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombotic Thrombocytopenic Purpura
79%
Antiphospholipid Syndrome
23%
Thrombosis
20%
Von Willebrand Factor Cleaving Proteinase
19%
Cardiovascular Disease
18%
Remission
17%
Antiphospholipid Antibody
15%
Bleeding
15%
Rituximab
12%
Disease
11%
Posttraumatic Stress Disorder
11%
Von Willebrand Factor
9%
Venous Thromboembolism
8%
Prostate Cancer
8%
Syndrome
7%
Pathophysiology
7%
Prevalence
6%
Uveitis
5%
Sickle Cell Anemia
5%
Hydroxycarbamide
5%
Infliximab
5%
Cross Sectional Study
5%
Rendu Osler Weber Disease
5%
Blood Clotting Disorder
5%
Von Willebrand Disease
5%
Disseminated Intravascular Clotting
5%
Idiopathic Thrombocytopenic Purpura
5%
Eculizumab
5%
Castration Resistant Prostate Cancer
5%
Graft Versus Host Reaction
5%
Caplacizumab
5%
Heart Infarction
5%
Recurrence Free Survival
5%
Anticoagulant Agent
5%
Thrombocytopenia
5%
